Syros Pharmaceuticals
Redefining the power of small molecules to control gene expression and to provide a profound benefit for patients.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $45.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 86 % | (3 %) | 662 % | 56 % | (37 %) | (33 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (4828 %) | (2960 %) | (3785 %) | (522 %) | (410 %) | (879 %) | (1182 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (4906 %) | (3038 %) | (3806 %) | (557 %) | (369 %) | (636 %) | (1656 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 3805 % | 2448 % | 2939 % | 504 % | 425 % | 752 % | 1088 % |
Source: Company filings or news article
Related Content
Syros Pharmaceuticals is a biopharmaceutical company focused on developing innovative gene control medicines to treat cancer and genetic diseases. The company operates in the healthcare and biotechnology market, primarily serving patients with acute myeloid leukemia and select solid tumors. Syros' business model revolves around the research, development, and commercialization of small molecule therapies that precisely control gene expression. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary medicines. Syros is advancing a pipeline that includes two investigational medicines in clinical trials and multiple programs in preclinical development. The company's approach leverages its expertise in gene control to create targeted therapies that aim to transform patient outcomes.
Keywords: gene control, small molecules, cancer therapy, genetic diseases, biopharmaceutical, acute myeloid leukemia, solid tumors, clinical trials, biotechnology, innovative medicines.
Tech stack
Investments by Syros Pharmaceuticals
Edit